Yaoshibang, a Guangzhou-based business-to-business (B2B) pharmaceutical trading platform, announced that it has completed a US$133 million new round of financing from Tiger Global Management, DCM Ventures and China’s H Capital. The new funding comes on the heels of a RMB420 million (US$65.7 million) series C round led by Shunwei Capital and DCM Ventures in June, […]

Tiger Global Management Co-Invests $133M In China’s B2B Pharma Trading Firm Yaoshibang appeared first on China Money Network.